Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

5

**Rebound after the end of all assigned treatmentBI 201335 once-daily at 240mg plus SOC provided positive Phase 2 results in this very difficult-to-treat patient population. As is seen in SILEN-C1, a three-day LI with SOC was associated with decreased viral response. Phase 3 trials of BI 201335 are in preparation.

The most frequent dose-dependent AEs in BI 201335 treatment groups were gastrointestinal disorders, jaundice resulting from unconjugated hyperbilirubinemia, and mild to moderate rash or photosensitivity. Serious or severe AEs were reported more frequently in the BI 201335 240mg BID with LI group. Discontinuations due to adverse events ranged from 4 percent in the BI 201335 240mg QD without LI group to 23 percent in the BI 201335 240mg BID with LI group.

Additional HCV Studies to be Presented at EASL

  • SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV
    (Poster #1231. S. Pol, et al., April 2, 9:00 a.m.-6:00 p.m. CET)
  • Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI 201335
    (Poster #1236. R. Sane, et al., April 2, 9:00 a.m.-6:00 p.m. CET)
  • BI 201335 pharmacokinetics and early effect on viral load in HCV genotype-1 patients
    (Poster #1249. C. Yong, et al., April 2, 9:00 a.m.-6:00 p.m. CET)
  • Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BILB 1941
    (Poster #1215. G. Kukolj, et al., April 2, 9:00 a.m.-6:00 p.m. CET)

  • About Hepatitis C Virus (HCV)HCV is an infectious disease of the liver and is a leading cause of chronic liver disease and liver transplant. The number of individuals chronically infected with HCV globally has been estimated at 170 million, with three to four million new infections occurring each year. Only about 20-45 percent of patient
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Multiple ... in demyelination, axonal transection, and neurodegeneration. The myelin sheath ... immune system, which targets neurons within the central nervous ... which the damage of the myelin sheath causes disruption ...
    (Date:8/29/2014)... Aug. 29, 2014  Pacific Medical Data Solutions is ... website design . The main website, along with the ... company,s new services and content relevant to the medical ... streamlined design, viewers can now better understand how PMDS ... practices and create a more visible platform about medical ...
    (Date:8/29/2014)... , Aug. 29, 2014 Research and ... Orthopedic Soft Tissue Repair Devices Market 2014-2018" report ... are the mass of cells that connect, support, or ... tissues such as tendons, ligaments, cartilage, fascia, and other ... of these tissues with age result in wear and ...
    Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
    ... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
    ... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
    Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
    (Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
    (Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- If you have ... more serious treatment later, an expert says. A bunion ... big toe when bone or tissue moves out of place ... untreated, bunions can cause debilitating pain and may require surgery ... at CentraState Medical Center in Freehold, N.J. To prevent ...
    (Date:8/29/2014)... IL (PRWEB) August 29, 2014 A ... hearing wellness solutions, is on its way to the ... the San Diego Convention Center to exhibit and demonstrate ... work in high-noise industrial environments. Etymotic’s safety earphones and ... wearable technology devices at the show. , The ...
    (Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
    (Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
    Breaking Medicine News(10 mins):Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
    ... ... with AiRISTA to provide Wi-Fi-based RFID solutions. , ... Sparks, Maryland (PRWEB) September 14, 2009 ... (DCC) to promote, distribute, implement and support AiRISTA,s solutions and technologies ( www.AiRISTA.com ...
    ... works in different way than standard medicines , SUNDAY, ... people whose high blood pressure cannot be controlled by ... researchers report. , Substantial reductions in blood pressure were ... people who were still hypertensive despite trying three or ...
    ... ... has been awarded the prestigious Gold certification from Cisco systems for ... The Certification recognizes High Point,s expert level of achievement for advanced ... Data Center. Gold Certified Partners are considered extensions of Cisco,s support ...
    ... the first ever found to prevent cartilage loss from osteoarthritis ... cartilage that has been lost to osteoarthritis, according to an ... American Society for Bone and Mineral Research in Denver. While ... osteoarthritis that develops following knee injuries, according to the study ...
    ... say they,ll donate than do, leaving long waits for transplants ... and large say they support the idea of donating some ... lives, reality presents a different picture. , Just 38 percent ... organ and tissue donors, according to a report this year ...
    ... , FRAMINGHAM, Mass., Sept. 11 Philips Lifeline ... subscribers of its personal emergency response service to alert users of ... is used primarily by seniors living independently in their homes who ... button" worn on the body, users connect to a remote monitoring ...
    Cached Medicine News:Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 3Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 4Health News:For Organ Donation, Intent and Reality Don't Align 2Health News:For Organ Donation, Intent and Reality Don't Align 3Health News:Lifeline Issues Safety Notice to Subscribers 2
    Disposable Microscissors: Vertical, 90...
    Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
    Claes Shielded Retinotomy Scissors, Curved Vertical...
    ... is intended for qualitatively detecting antibodies to ... The test is indicated for testing persons ... aid in the presumptive laboratory diagnosis of ... for self-testing, and this test is not ...
    Medicine Products: